Mark Murcko Ph.D.
Net Worth
Last updated:
What is Mark Murcko Ph.D. net worth?
The estimated net worth of Dr. Mark Murcko Ph.D. is at least $5,043,387 as of 8 Sep 2022. He owns shares worth $3,389,637 as insider, has earned $748,750 from insider trading and has received compensation worth at least $905,000 in Relay Therapeutics, Inc..
What is the salary of Mark Murcko Ph.D.?
Dr. Mark Murcko Ph.D. salary is $181,000 per year as Co-Founder & Director in Relay Therapeutics, Inc..
How old is Mark Murcko Ph.D.?
Dr. Mark Murcko Ph.D. is 65 years old, born in 1960.
What stocks does Mark Murcko Ph.D. currently own?
As insider, Dr. Mark Murcko Ph.D. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Relay Therapeutics, Inc. (RLAY) | Co-Founder & Director | 996,952 | $3.4 | $3,389,637 |
What does Relay Therapeutics, Inc. do?
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Mark Murcko Ph.D. insider trading
Relay Therapeutics, Inc.
Dr. Mark Murcko Ph.D. has made only one insider trade between 2020-2022, according to the Form 4 filled with the SEC. He sold 25,000 units of RLAY stock worth $748,750 on 8 Sep 2022.
As of 8 Sep 2022 he still owns at least 996,952 units of RLAY stock.
Relay Therapeutics key executives
Relay Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Donald A. Bergstrom M.D., Ph.D. (53) Executive Vice President and Head of R&D
- Dr. Mark Murcko Ph.D. (65) Co-Founder & Director
- Dr. Sanjiv K. Patel MBBS, M.A., M.D., M.B.A. (51) Chief Executive Officer, Pres & Director
- Mr. Alexis A. Borisy A.M. (53) Co-Founder & Independent Chairman
- Mr. Brian R. Adams J.D. (51) Gen. Counsel & Sec.